From the American Academy of Ophthalmology

Using a health care database, investigators analyzed the stroke rate across three mutually exclusive time periods: before the availability of bevacizumab or ranibizumab, the period of bevacizumab dominant AMD therapy, and the period of ranibizumab dominant therapy. They found no change in the rate of hospitalization for stroke among seniors with retinal disease with the introduction of anti-VEGF therapy, and that the stroke rates in the bevacizumab and ranibizumab periods were not different. Ophthalmology, September 2012